Hetero ties up with Gilead for Remdesivir
Hetero will be supplying Remdesivir in 127 countries, including India, subject to regulatory approvals in respective countries
Hyderabad: Hetero has announced that it has entered into a licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of "Remdesivir" for the treatment of Covid-19. Under this licensing deal, Hetero will be supplying Remdesivir in 127 countries, including India, subject to regulatory approvals in respective countries.
Dr. B. Partha Saradhi Reddy, Chairman, Hetero Group of Companies, commented: "Hetero is pleased to partner with Gilead to enable access for this important drug to India and other developing countries at this crucial time. This agreement also illustrates the significance of global collaboration and the need for coming together to fight the health crises impacting humanity. Hetero has developed this product in India and has already been working with the government, ICMR, and DCGI for necessary studies and approvals to bring this product to treat COVID-19 patients in India."
"Remdesivir will be manufactured in our formulation facility in Hyderabad, India, which has been approved by stringent global regulatory authorities such as USFDA and EU, among others. Hetero has developed the fully vertically integrated supply chain for this product complementing the "Make in India" campaign as defined by our Hon'ble Prime Minister, "he added
U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for the investigational antiviral Remdesivir to treat COVID-19.
Remdesivir is authorized for the treatment of hospitalized patients with severe COVID-19 disease. The optimal duration of treatment is still being studied in ongoing clinical trials.
Under the EUA, both 5-day and 10-day treatment durations are suggested, based on the severity of the disease. The authorization is temporary and does not take the place of the formal new drug application submission, review, and approval process. The EUA allows for the distribution and emergency use of Remdesivir only for the treatment of COVID-19; Remdesivir remains an investigational drug and is not approved anywhere globally including the US and India.
Read also: Cipla becomes 2nd firm to enter tie-up with Gilead to make remdesivir in India
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.